Novartis: CHMP Grants Accelerated Assessment To Heart Failure Medicine LCZ696

November 28, 2014 6:39 AM

12 0

( - Swiss pharmaceutical giant Novartis AG ( NVS ) said the Committee for Medicinal Products for Human Use or CHMP has granted accelerated assessment to LCZ696, an investigational medicine for patients with heart failure with reduced ejection fraction or HfrEF.

According to the company, the expedited review procedure is granted infrequently by the EMA and has never been awarded in the cardiovascular area until now.

Read more

To category page